Cancer vaccines

Anti-Cancer Drugs

Volumn 8, Issue 8, 1997, Pages 727-733

  Durrant, L G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer; Vaccine

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; DIFFERENTIATION ANTIGEN; GANGLIOSIDE GM2; HEAT SHOCK PROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BREAST CANCER; CANCER; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; MELANOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MELANOMA; OVARIAN NEOPLASMS; VACCINES, DNA;

EID: 0030763396     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199709000-00001     Document Type: Review

References (39)

1. Rosenberg SA. Cell transfer therapy. Philadelphia: Lipincott 1995.
2. Fairchild PJ, Wraith DC. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol today 1996; 17: 80-4.
3. Baskar S. Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunothur 1996; 43: 165-73
4. Hamilton WB, Helling F, Lloyd KO, et al. Ganglioside expression on human-malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993; 53: 566-73.
5. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147-65.
6. Kitamura K, Livingston PO, Fortunato SR, et al. Serological response patterns of melanoma patients immunized with a Gm2 ganglioside conjugate vaccine. Proc Nat Acad Sci USA 1995; 92: 2805-9.
7. Boon T, Goayewski TF, Coulie PG. From defined antigens to effective immunisation. Immunol Today 1995; 16: 334-6.
8. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996; 47: 481-91.
9. Van Pel A, van der Bruggen P, Coulie PG, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995; 145: 229-50.
10. Tsomides TJ, Eisen HN. T-cell antigens in cancer. Proc Natl Acad Sci USA 1994; 91: 3487-9.
11. Jager E, Ringhoffer M, Dienes HP, et al. Granulocytemacrophage-colony-stimulating factor enhances immune-responses to melanoma-associated peptides in-vivo. Int J Cancer 1996; 67: 54-62.
12. Riethmuller G, Scheidergadicke E, Schlimok G, et al. Randomized trial of monoclonal-antibody for adjuvant therapy of resected Dukes-C colorectal carcinoma. Lancet 1994; 343: 1177-83.
13. Chattopadhyay P, Starkey J, Morrow WJW, et al. Murine monoclonal anti-idiotype antibody breaks unresponsiveness and induces a specific antibody response of human melanoma associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci USA 1992; 89: 2684-8.
14. Herlyn D, Wettendorff M, Schmoll E, et al. Anti-idiotype immunization of cancer-patients - modulation of the immune-response. Proc Natl Acad Sci USA 1987; 84: 8055-9.
15. Fagerberg J, Hjelm AL, Ragnhammar P, et al. Tumor-regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T-lymphocytes. Cancer Res 1995; 55: 1824-7.
16. Austin EB, Robins RA, Durrant LG, et al. Human monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36. Immunology 1989; 67: 525-30.
17. Austin EB, Robins RA, Baldwin RW, et al. Induction of delayed-hypersensitivity to human tumor-cells with a human monoclonal antiidiotypic antibody. J Natl Cancer Inst 1991; 83: 1245-8.
18. Robins RA, Denton GWL, Hardcastle JD, et al. Antitumor immune-response and interleukin-2 production induced in colorectal-cancer patients by immunization with human monoclonal antiidiotypic antibody. Cancer Res 1991; 51: 5425-9.
19. Denton GWL, Durrant LG, Hardcastle JD, et al. Clinical outcome of colorectal-cancer patients treated with human monoclonal antiidiotypic antibody. Int J Cancer 1994; 57: 10-4.
20. Durrant LG, Buckley TJD, Denton GWL, et al. Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994; 54: 4837-40.
21. Durrant LG, Buckley DTJ, Spendlove I, et al. Monoclonal antibodies as cancer vaccines. Ann Oncol, unpublished.
22. Durrant LG, Denton GWL, Jacobs E, et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int J Cancer 1992; 50: 811-6.
23. Foon KA, Chakraborty M, John WJ, et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96: 334-2.
24. Conry RM, LoBuglio AF, Curiel DT. Phase I a trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancer. Hum Gene Ther 1996; 7: 755.
25. Whalen RG, Davis HL. Short analytical review. DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin Immunol Immunopathol 1995; 75: 1-12.
26. Irvine KR, Rao JB, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-45.
27. Conry RM, Lobuglio AF, Kantor J, et al. Immune-response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54: 1164-8.
28. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-90.
29. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex restricted antitumour immunity. J Exp Med 1996; 183: 7-11.
30. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317-22.
31. Gabrilovitch D, Ciernic IF. Dendritic cells grown from bone marrow precursors but not mature dendritic cells from tumor bearing mice can be effective antigen carriers in the therapy of established tumours. Proc Am Ass Cancer Res 1996: 37: 475.
32. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumours with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
33. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995; 346: 1399-400.
34. Jung S, Schluesener HJ. Human T lymphocytes recognise a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173: 273-6.
35. Ciernik IF, Berzofsky J, Carbone DP. Mutant oncopeptide immunisation induces CTL specifically lysing tumor-cells endogenously expressing the corresponding intact mutant P53. Hybridoma 1995; 14: 139-42.
36. Blachere NE, Udono H, Janetzki S, et al. Heat-shock protein vaccines against cancer. J Immunother 1993; 14: 352-6.
37. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumour mucin-based immunity and cancer vaccines. Immunol Rev 1995; 145: 61-89.
38. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu proto-oncogene in human-breast and ovarian-cancer. Science 1989; 244: 707-12.
39. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev 1995; 145: 33-59.